Last month, a US-based healthtech founder asked me where he should incorporate his AI company. He was deciding between Delaware and Ontario. I told him Ontario — and he looked at me like I'd suggested he build a spaceship out of duct tape. Six weeks later, he moved his entire dev team to Toronto. Here's why.
At Autor, we've spent the last two years building Loquent — a production voice AI platform that handles thousands of automated calls per month for healthcare and dental clients across Canada. We've shipped AI into regulated healthcare environments, navigated PIPEDA and PHIPA compliance from day one, and watched the US regulatory landscape turn into a minefield while Canada quietly built something better. I'm not saying Canada is perfect. I'm saying that right now, in June 2026, if you're starting a healthcare AI company, you're making a mistake by defaulting to the US.
The Regulatory Argument Everyone Gets Wrong
The common take is that the US is more "innovation-friendly" because HIPAA is well-understood and the FDA has been approving AI/ML medical devices since 2017. That's true — if you're building a diagnostic imaging tool that fits neatly into the existing SaMD framework. For everything else, especially conversational AI, voice agents, ambient scribes, and patient-facing automation, the US is a regulatory grey zone that's getting greyer.
Canada's AIDA (Artificial Intelligence and Data Act) died in Parliament when it was prorogued in January 2025. Most people read that as "Canada has no AI regulation." I read it differently: Canada has no bad AI regulation. What we do have is PIPEDA — a principles-based privacy framework that actually works for AI development.
Here's the practical difference. HIPAA is entity-specific. It only covers "covered entities" — healthcare providers, insurers, and clearinghouses. Your AI startup processing voice calls for a dental clinic? You might not be a covered entity, but you're still handling PHI, and the legal exposure is enormous and unclear. PIPEDA covers all commercial activity involving personal information. There's no ambiguity about whether you're in scope. You are. And because PIPEDA's 10 Fair Information Principles are consent-based rather than entity-based, you can actually build a compliance architecture that makes sense for an AI product.
Ontario's PHIPA adds a healthcare-specific layer on top. Section 29 requires Canadian data residency. That sounds like a restriction, but it's actually a competitive moat. If your data stays in Canada, you're compliant by default with the data sovereignty requirements that are now hitting US companies as a surprise. The EU's adequacy decisions, cross-border transfer restrictions, and provincial approval requirements all become simpler problems when your infrastructure is already Canadian.
The Talent Math
Toronto is now the third-largest tech talent pool in North America — over 285,000 technology workers in software, systems, and engineering roles. Only the Bay Area and New York Metro are bigger. Toronto's tech talent grew 44% over five years. The Vector Institute, University of Toronto, and the broader Waterloo-Toronto corridor produce more ML engineers per capita than anywhere except maybe London.
But here's the number that actually matters: 30-40% cost savings compared to equivalent US hires. A senior ML engineer in San Francisco costs $250-350K fully loaded. In Toronto, that same engineer — often trained at the same institutions, publishing in the same conferences — costs $160-220K CAD, which is roughly $115-160K USD.
And Canada's Global Talent Stream visa processes international hires in two weeks. Not two months. Two weeks. We've used this at Autor to bring in specialized talent from India and Eastern Europe without the H-1B lottery or the 8-month USCIS processing times that US startups just accept as normal.
The Healthcare AI Market Nobody's Watching
The dental AI market alone is projected to grow from $516M (2025) to $3.9B by 2035 — a 22.5% CAGR. The Canadian Dental Association made AI its central theme at CDA Presents 2026 in April. This isn't fringe adoption. The professional governing bodies are actively pushing clinics to modernize.
We see this firsthand with Loquent. When we started building voice AI for dental clinics, the conventional wisdom was that Canadian healthcare was too conservative, too slow-moving, too resistant to automation. That turned out to be completely wrong. What Canadian clinics are is compliance-conscious. They don't want to be first, but they absolutely want to adopt technology that's already proven AND compliant. Once we showed that Loquent handled PHIPA-compliant call handling with Canadian data residency, the objection wasn't "we don't want AI" — it was "how fast can you deploy."
The competitive landscape is still early. DentalAssist.ai out of Burlington is doing interesting work. A few US-based companies are trying to enter the Canadian market but stumbling on compliance. The window for building a dominant Canadian healthcare AI company is open right now, and it won't stay open forever.
The SR&ED Advantage Nobody Talks About
Canada's Scientific Research and Experimental Development (SR&ED) tax credit covers up to 35% of eligible R&D spend for Canadian-controlled private corporations. If you're building an AI product, most of your engineering work qualifies. We've used SR&ED at Autor every year, and the refund effectively subsidizes our entire research pipeline.
The US has R&D tax credits too, but they're far less generous and the 2022 amortization rules made them worse. For early-stage healthcare AI companies burning cash on model development, prompt engineering, and integration work, the SR&ED refund is often the difference between having 12 months of runway and having 16 months.
Combine SR&ED with lower salaries, Canadian data residency compliance, and the fact that $1 USD buys you roughly $1.38 CAD of engineering output, and the unit economics of building in Canada are hard to argue against.
The Contrarian Bet
I know what the counterarguments are. The US healthcare market is 10x larger. US VCs have deeper pockets. The FDA approval pathway, despite its flaws, is a known quantity.
All true. And all beside the point if you're building voice AI, conversational agents, patient-facing automation, or ambient clinical intelligence — the categories that are actually growing fastest. For these products, the regulatory clarity, talent economics, and compliance infrastructure in Canada aren't just "comparable" to the US. They're better.
The US is heading toward a patchwork of state-level AI regulations. California, Colorado, and Illinois already have divergent frameworks. HIPAA wasn't designed for AI and hasn't been meaningfully updated. The FDA is doing innovative work with agentic AI reviews, but that's for medical devices — not for the voice agent that answers your clinic's phones.
Canada has a single federal privacy framework, provincial health information acts that are consistent in their principles, a regulatory gap that gives startups room to build without premature compliance burden, and a talent pool that keeps getting deeper.
We're not the only ones who've noticed. The healthtech founder I mentioned at the top? He told me his Toronto team shipped their MVP three months faster than his US team had projected, at 40% of the budget. That's not a fluke. That's the structural advantage of building where the fundamentals align.
Key Takeaways
PIPEDA's principles-based approach works better for AI than HIPAA's entity-based model. If you're building any healthcare AI product that isn't a traditional medical device, Canada's regulatory framework gives you clearer guardrails with less ambiguity.
The talent economics are unbeatable. Toronto's 285,000+ tech workers, 30-40% cost savings, and two-week visa processing make it the most capital-efficient place in North America to build an AI team.
Canadian data residency is a moat, not a limitation. As cross-border data transfer requirements tighten globally, being Canadian-first means you're already compliant where others are scrambling.
SR&ED extends your runway by 20-30%. No other G7 country offers R&D tax credits this generous for early-stage AI companies.
The dental and healthcare AI market is moving now. The CDA made AI its 2026 theme. Clinics are buying. The competitive window is open but closing.
If you're building something similar, we'd love to hear about it. Reach out at hello@autor.ca or visit autor.ca.
Top comments (0)